Nosocomial InfectionsOncoped2006NCT00843804
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
An observational study of Nosocomial Infections and Bloodstream Infection, run by University Hospital, Bonn at 1 site in Switzerland.
Trial summary
The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients. Read more about this study
- Who is it for?
- Ages Up to 21 years
- Conditions the study is for
- Nosocomial Infections, Bloodstream Infection, Invasive Aspergillosis
- How many people
- 50 participants
- Where
- 1 siteSwitzerland
- Study dates
- Mar 2007to Jun 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Pediatric patients with cancer during intensive induction / reinduction treatment (including conventional chemotherapy, radiotherapy and stem cell transplantation).
Who may be able to join
- pediatric cancer patients receiving inpatient treatment with chemotherapy, -
- radiotherapy or stem cell transplantation
Who cannot join
- no informed consent
- no inpatient treatment
Trial locations and contacts
1 site in 1 country.
Switzerland1 site, 1 recruiting
- Recruiting
Children's Hospital, Pediatric Oncology UNit
Bern, CH 3010
Roland Ammann, MD, 0041316329315, rolan.ammann@insel.ch
Roland Ammann, MD
About this study
Official title: Prospective Surveillance for Nosocomial Infections and Catheter-related Thrombotic Events in Pediatric Patients
The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients.
Read the detailed description
Type of study:
Prospective multicenter surveillance study referring to file data collected routinely during the management of infectious and thrombotic complications in high risk pediatric cancer patients.
Primary aims of the Oncoped 2006 Study
- To describe the epidemiology of selected nosocomial infections in pediatric cancer patients as well on the unit level as in a reference database of cumulative data from a prospective multicenter surveillance perspective.
- To allow the participating institution
- to compare its own results with other centers and with the reference database (median and 75. percentile).
- to reduce the incidence density of nosocomial infections and the incidence rate of catheter-associated infections in pediatric cancer patients.
- To promote patient's safety by means of quality assurance and a reduction of nosocomial infections.
- To describe objective outcome variables related to the documented NI events (mortality, duration of hospitalization, need for intensive care, need for surgical interventions)
- To intensify the practical collaboration of the health care team with infection control personnel and infectious disease specialists in this clinical context.
- To describe the distribution of bacterial pathogens of blood stream infections and to determine the sensitivity (minimal inhibitory concentration) of bacterial pathogens detected in blood cultures to first and second line antimicrobial agents in this high risk population with a standardized method (central reference laboratory).
- To detect bacterial isolates with emerging types of antimicrobial resistance.
- To describe the therapeutic use of antibacterial and antifungal agents in pediatric cancer patients related to nosocomial infections.
- To describe the incidence and incidence density of invasive Aspergillosis in pediatric cancer patients.
- To describe the clinical impact of common and emerging viral respiratory pathogens (RSV, Influenza, hMPV, hCoV, hBoV) in pediatric cancer patients with nosocomial lower respiratory tract infection (central reference laboratory for emerging viral pathogens).
- What is the incidence and incidence rate (per 1000 catheter utilization days) of thrombotic events in pediatric cancer patients and in patients with hemophilia, who have a CVAD in use?
- How many of the children with an event do have congenital risk factors (thrombophilia)?
- What are the objective outcome parameters in this population considering antithrombotic treatment (at the discretion of the attending physicians)?
- Keywords
- nosocomial infection, bloodstream infection, central venous catheter, invasive Aspergillosis, Clostridium difficile associated disease
- Medical subject headings
- Cross Infection, Sepsis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2009 (estimated)
- Study startMar 2007
- Study completionJun 2010 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Nosocomial InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bonn
- Sponsor type
- University, hospital or other
- Investigators
- Arne Simon, MD, Principal investigator, Children's Hospital Medical Center, University of Bonn, GermanyRoland Ammann, MD, Study director, Children's Hosptial, Bern, SwitzerlandHans-Jürgen Lawas, MD, Study chair, Children's Hospital Medical Center, Düsseldorf, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00843804
- Sponsor's protocol ID
- 03/07
- Acronym
- Oncoped2006
- Status last verified
- Feb 2009
- First submitted
- 12 Feb 2009
- Last updated
- 28 Jun 2010
- Results posted
- No
- Data monitoring committee
- No
Publications
Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol. 2000 Sep;21(9):592-6. doi: 10.1086/501809.
PubMed 11001263Simon A, Bode U, Fleischhack G, Kramer M. Surveillance of nosocomial infections in pediatric cancer patients. Am J Infect Control. 2005 Dec;33(10):611. doi: 10.1016/j.ajic.2005.09.005. No abstract available.
PubMed 16330311Simon A, Fleischhack G, Wiszniewsky G, Hasan C, Bode U, Kramer MH. Influence of prolonged use of intravenous administration sets in paediatric cancer patients on CVAD-related bloodstream infection rates and hospital resources. Infection. 2006 Oct;34(5):258-63. doi: 10.1007/s15010-006-5646-y.
PubMed 17033749Simon A, Groger N, Wilkesmann A, Hasan C, Wiszniewsky G, Engelhart S, Kramer MH, Bode U, Ammann RA, Fleischhack G. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents. 2006 Nov;28(5):417-22. doi: 10.1016/j.ijantimicag.2006.08.007. Epub 2006 Oct 12.
PubMed 17046210Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U, Fleischhack G. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer. 2007 Feb;15(2):213-20. doi: 10.1007/s00520-006-0125-7. Epub 2006 Aug 30.
PubMed 16944217
Study at a glance
From the registry record, last updated by the sponsor on 28 Jun 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Surveillance for Nosocomial Infections and Catheter-related Thrombotic Events in Pediatric Patients
- ClinicalTrials.gov ID
- NCT00843804
- Acronym / sponsor ID
- Oncoped2006 / 03/07
- Keywords
- nosocomial infection, bloodstream infection, central venous catheter, invasive Aspergillosis, Clostridium difficile associated disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University Hospital, BonnUniversity, hospital or other
- Study start
- Mar 2007
- Study completion
- Jun 2010 (estimated)
- First posted
- 13 Feb 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients.
Detailed description
Type of study:
Prospective multicenter surveillance study referring to file data collected routinely during the management of infectious and thrombotic complications in high risk pediatric cancer patients.
Primary aims of the Oncoped 2006 Study
- To describe the epidemiology of selected nosocomial infections in pediatric cancer patients as well on the unit level as in a reference database of cumulative data from a prospective multicenter surveillance perspective.
- To allow the participating institution
- to compare its own results with other centers and with the reference database (median and 75. percentile).
- to reduce the incidence density of nosocomial infections and the incidence rate of catheter-associated infections in pediatric cancer patients.
- To promote patient's safety by means of quality assurance and a reduction of nosocomial infections.
- To describe objective outcome variables related to the documented NI events (mortality, duration of hospitalization, need for intensive care, need for surgical interventions)
- To intensify the practical collaboration of the health care team with infection control personnel and infectious disease specialists in this clinical context.
- To describe the distribution of bacterial pathogens of blood stream infections and to determine the sensitivity (minimal inhibitory concentration) of bacterial pathogens detected in blood cultures to first and second line antimicrobial agents in this high risk population with a standardized method (central reference laboratory).
- To detect bacterial isolates with emerging types of antimicrobial resistance.
- To describe the therapeutic use of antibacterial and antifungal agents in pediatric cancer patients related to nosocomial infections.
- To describe the incidence and incidence density of invasive Aspergillosis in pediatric cancer patients.
- To describe the clinical impact of common and emerging viral respiratory pathogens (RSV, Influenza, hMPV, hCoV, hBoV) in pediatric cancer patients with nosocomial lower respiratory tract infection (central reference laboratory for emerging viral pathogens).
- What is the incidence and incidence rate (per 1000 catheter utilization days) of thrombotic events in pediatric cancer patients and in patients with hemophilia, who have a CVAD in use?
- How many of the children with an event do have congenital risk factors (thrombophilia)?
- What are the objective outcome parameters in this population considering antithrombotic treatment (at the discretion of the attending physicians)?
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- Up to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Pediatric patients with cancer during intensive induction / reinduction treatment (including conventional chemotherapy, radiotherapy and stem cell transplantation).
Key inclusion criteria (2 listed)
- pediatric cancer patients receiving inpatient treatment with chemotherapy, -
- radiotherapy or stem cell transplantation
Key exclusion criteria (2 listed)
- no informed consent
- no inpatient treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jun 2010.
- Background: PubMed 11001263Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol. 2000 Sep;21(9):592-6. doi: 10.1086/501809.
- Background: PubMed 16330311Simon A, Bode U, Fleischhack G, Kramer M. Surveillance of nosocomial infections in pediatric cancer patients. Am J Infect Control. 2005 Dec;33(10):611. doi: 10.1016/j.ajic.2005.09.005. No abstract available.
- Background: PubMed 17033749Simon A, Fleischhack G, Wiszniewsky G, Hasan C, Bode U, Kramer MH. Influence of prolonged use of intravenous administration sets in paediatric cancer patients on CVAD-related bloodstream infection rates and hospital resources. Infection. 2006 Oct;34(5):258-63. doi: 10.1007/s15010-006-5646-y.
- Background: PubMed 17046210Simon A, Groger N, Wilkesmann A, Hasan C, Wiszniewsky G, Engelhart S, Kramer MH, Bode U, Ammann RA, Fleischhack G. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents. 2006 Nov;28(5):417-22. doi: 10.1016/j.ijantimicag.2006.08.007. Epub 2006 Oct 12.
- Background: PubMed 16944217Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U, Fleischhack G. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer. 2007 Feb;15(2):213-20. doi: 10.1007/s00520-006-0125-7. Epub 2006 Aug 30.
Related trials for Nosocomial Infections
RecruitingPhase 4
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Blood Stream Infections, Ventilator Associated Pneumonia
RecruitingObservational study
IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients
Critical Illness, Intensive Care Patients
Recruiting
Nosocomial Respiratory Virus Infection
Nosocomial Infections
RecruitingObservational study
Natural History of Clostridioides Difficile Infection
Clostridium Difficile Infection, Health Care Associated Infection
Not yet recruiting
Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial
Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arne Simon, MD principal investigator
Children's Hospital Medical Center, University of Bonn, Germany
Roland Ammann, MD study director
Children's Hosptial, Bern, Switzerland
Hans-Jürgen Lawas, MD study chair
Children's Hospital Medical Center, Düsseldorf, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Nosocomial Infections and Bloodstream Infection, run by University Hospital, Bonn at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Jun 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Arne Simon, MD (004922828733254, asimon@ukb.uni-bonn.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00843804, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2010.